Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of bomedemstat versus hydroxyurea in cytoreductive-treatment-naive essential thrombocythemia
MOH_2024-03-17_013320Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in thrombocythemia comparing Bomedemstat arm with Hydroxyurea arm (2 arms). Primary endpoint: Durable clinical and hematologic response. Started May 2024; status: recruiting.
02
Drugs
bomedemstathydroxyurea
03
Conditions
thrombocythemia
Beyond the preview
Go deeper on MOH_2024-03-17_013320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-03-17_013320.